<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636659</url>
  </required_header>
  <id_info>
    <org_study_id>CR179-17</org_study_id>
    <secondary_id>CTRI/2018/04/013350</secondary_id>
    <nct_id>NCT03636659</nct_id>
  </id_info>
  <brief_title>Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition</brief_title>
  <official_title>Multi-Center, Open-Label, Randomized, Two Treatment, Parallel, Single Period, Multiple-Dose, Steady State, Global Bioequivalence Study of Amphotericin B Liposome for Injection 50mg /Vial in Patients With Visceral Leishmaniasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurobindo Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Axis Clinicals Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aurobindo Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for
      injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection
      of Astellas Pharma US, Inc., in patients with Visceral Leishmaniasis under fed condition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-Center, Open-Label, Randomized, Two treatment, Parallel, Single period, Multiple-Dose,
      Steady state, Global Bioequivalence study of Amphotericin B Liposome for Injection 50mg /vial
      of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) Liposome for Injection 50mg/vial
      of Astellas Pharma US, inc. in patients with Visceral Leishmaniasis under fed
      condition.Sufficient number of patients will be enrolled to have 140 evaluable patients. (90
      to 100 patients from India and 40 to 50 patients from Bangladesh).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Actual">April 5, 2019</completion_date>
  <primary_completion_date type="Actual">April 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of Cmax-ss, Maximum concentration over the steady state dosing interval</measure>
    <time_frame>05 days</time_frame>
    <description>To establish bioequivalence limits within 80-125 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimation of AUC0-tau, Area under the plasma concentration time curve over the steady state dosing interval</measure>
    <time_frame>05 days</time_frame>
    <description>To establish bioequivalence limits within 80-125 %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Cmin-ss</measure>
    <time_frame>05 days</time_frame>
    <description>Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Cavg-ss</measure>
    <time_frame>05 days</time_frame>
    <description>Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tmax-ss</measure>
    <time_frame>05 days</time_frame>
    <description>Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Cpd</measure>
    <time_frame>05 days</time_frame>
    <description>Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Percentage Fluctuation</measure>
    <time_frame>05 days</time_frame>
    <description>Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Swing</measure>
    <time_frame>05 days</time_frame>
    <description>Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Amphotericin B Liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AmBisome Liposome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B Liposome</intervention_name>
    <description>Manufactured for: Auromedics Pharma LLC, USA</description>
    <arm_group_label>Amphotericin B Liposome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AmBisome (Amphotericin B) Liposome</intervention_name>
    <description>Marketed by: Astellas Pharma US, Inc. USA</description>
    <arm_group_label>AmBisome Liposome</arm_group_label>
    <other_name>AmBisome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged between 18 to 65 years (both inclusive)

          -  Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration,
             weight loss and splenomegaly)

          -  Presence of amastigotes (Leishmania Donovani bodies) at screening detected by rK39
             dipstick test.

          -  Female subjects of childbearing potential must have a negative serum pregnancy test at
             enrolment and be willing to use a reliable method of birth control, i.e. barrier
             method, intrauterine device, or tubal ligation.

          -  Ability to comply with all study requirements.

          -  Patients with Hb ≥ 6.0 g/dl

          -  Patients with platelets count ≥ 60,000/mm3

          -  Patients should be immunocompetent (e.g., white blood cell count ≥ 2500/ mm3)

          -  Patients and/ or LAR must be give written informed consent

          -  Patients with clinically acceptable results from all the screening laboratory
             parameters and investigations.

        Exclusion Criteria:

          -  Known allergy or hypersensitivity reactions to any components of conventional or
             liposomal Amphotericin B formulations.

          -  Any condition which the investigator thinks may prevent the patient from completing
             the study therapy and subsequent follow-up.

          -  Pregnant or lactating women

          -  Patients requiring dose adjustment during the study.

          -  Serum creatinine concentration greater than twice the upper limit of normal (ULN), AST
             or ALT value greater than 10 times the ULN

          -  Patients who are required to be on concomitant therapy with IV fat emulsions, such as
             total parental nutrition (TPN).

          -  Patients with total bilirubin levels &gt; 3 times the upper normal limits (i.e. &gt; 3.0
             mg/dl).

          -  Patient with clinically significant Hematopoietic, renal, hepatic and electrolyte
             disorders (Low level of Magnesium and potassium) will be excluded as per the
             discretion of Investigator

          -  Patients with Clinically significant screening laboratory parameters in the opinion of
             the investigator.

          -  Patients with any significant history of non-compliance to medical regimens or with
             inability to grant a reliable informed consent.

          -  History of uncontrolled diseases, such as thyroidal dysfunction, angina pectoralis,
             serious cardiac arrhythmias, serious heart failure, neuropsychiatric infection or
             disease.

          -  Patients with controlled and uncontrolled diabetes mellitus

          -  Patients with Uncontrolled hypertension will be excluded.

          -  Immunocompromised patients will be excluded from participating the study

          -  Patients with known positivity for human immunodeficiency virus (HIV), HBsAg and HCV.

          -  Positive results for drugs of abuse (benzodiazepines, opioids, amphetamines,
             cannabinoids, cocaine and barbiturates) in urine.

          -  Positive results for alcohol as detected by alcohol breath analyzer.

          -  History of difficulty with donating blood or difficulty in accessibility of veins.

          -  An unusual or abnormal diet, for whatever reason e.g. religious fasting.

          -  History of donation of blood (1 unit or 350 ml) within 90 days prior to receiving the
             first dose of investigational medicinal product in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagesh Meda, M.Pharm</last_name>
    <role>Study Chair</role>
    <affiliation>Aurobindo Pharma Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Subhra Lahiri, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Axis Clinicals Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sajid Mohd, MD</last_name>
    <role>Study Director</role>
    <affiliation>Axis Clinicals Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Krishna Pandey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rajendra Memorial Research Institute of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Shyam Sundar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kala-Azar medical Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Dinesh Mondal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoeal Disease Research b</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Centre for Diarrhoeal Disease Research b</name>
      <address>
        <city>Dhaka</city>
        <zip>1212</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kala-Azar medical Research Centre</name>
      <address>
        <city>Muzaffarpur</city>
        <state>Bihar</state>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajendra Memorial Research Institute of Medical Sciences</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <zip>800007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>India</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

